Patents by Inventor Helena de Puig Guixe

Helena de Puig Guixe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200308577
    Abstract: Disclosed herein are hydrogels comprising a polynucleotide-based structural component. Methods of altering a property of a hydrogel based on user-defined nucleic acid input sequences are also disclosed. In addition, various applications are described that utilize these hydrogels and methods.
    Type: Application
    Filed: January 31, 2020
    Publication date: October 1, 2020
    Applicant: Massachusetts Institute of Technology
    Inventors: James J. Collins, Helena de Puig Guixe, Luis Soenksen Martinez, Max English, Raphael Gayet, Nicolaas Angenent-Mari, Angelo S. Mao, Peter Q. Nguyen
  • Publication number: 20180372755
    Abstract: The present invention provides a multiplexed immunoassay which leverages stockpiled antibodies to detect whether a patient has been infected with an emerging disease which does not have specific antibodies raised against it (FIG. 1). The assay is preferably designed as a paper-based assay, which allows diagnosis at point of care (POC) and readout by eye or mobile phone. Paper-based rapid diagnostic tests (RDTs) are convenient, robust, and can be read out within minutes. The immunoassay of the invention combines the strategic use of nanoparticles of assorted colors with readily available stockpiled antibodies to one or more biomarkers of disease, particularly viral diseases.
    Type: Application
    Filed: June 22, 2018
    Publication date: December 27, 2018
    Inventors: Lee Gehrke, Helena de Puig Guixe, Irene Bosch, Jose Gomez-Marquez, Kimberly Hamad-Schifferli
  • Patent number: 9545383
    Abstract: The disclosure is directed to enabling reversible, on-demand remote control of blood clotting and clot dissolution. In one embodiment, a laser at one wavelength triggers release of a DNA thrombin inhibitor from one nanorod, which acts as an anticoagulant to stop blood clotting. Another wavelength triggers release of a specific antidote, which reverses the effect of the thrombin inhibitor, restoring blood clotting.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: January 17, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: Kimberly Hamad-Schifferli, Salmaan H. Baxamusa, Helena de Puig Guixe
  • Publication number: 20150272899
    Abstract: The disclosure is directed to enabling reversible, on-demand remote control of blood clotting and clot dissolution. In one embodiment, a laser at one wavelength triggers release of a DNA thrombin inhibitor from one nanorod, which acts as an anticoagulant to stop blood clotting. Another wavelength triggers release of a specific antidote, which reverses the effect of the thrombin inhibitor, restoring blood clotting.
    Type: Application
    Filed: March 31, 2015
    Publication date: October 1, 2015
    Applicant: Massachusetts Institute of Technology
    Inventors: Kimberly Hamad-Schifferli, Salmaan H. Baxamusa, Helena de Puig Guixe